Your session is about to expire
← Back to Search
SBRT + Pembrolizumab for Lung Cancer
Study Summary
This trial will test whether giving liver cancer patients both radiation therapy and systemic therapy together is feasible and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lung cancer has spread to my liver.I am 18 years old or older.I have an active TB, Hepatitis B, or Hepatitis C infection.I have not received a live vaccine in the last 30 days.I have not had any other cancer besides in situ cancers in the last year.I have been diagnosed with advanced liver disease.I can care for myself and am up and about more than 50% of my waking hours.I have an autoimmune disease treated in the last year, not including hormone therapy.My doctor has approved me for immune therapy.I've had durvalumab or radiation therapy not targeting my upper abdomen before.I am taking more than 10 mg of prednisone or its equivalent daily.My liver cancer cannot be treated with targeted radiation.My organs are functioning well.You have mental health or drug problems that could make it hard to follow the study rules or be safe.Your disease can be measured using specific guidelines.
- Group 1: Arm 1
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are actively engaged in the clinical trial?
"Correct. Per clinicaltrials.gov, this research project is currently searching for participants; the trial was first introduced on June 17th 2022 and recently revised on July 27th 2022. 12 patients must be recruited from a single location to participate in the study."
To what degree do the risks of Liver SBRT outweigh its potential benefits?
"The safety of liver SBRT has been calculated as a 1 due to its Phase 1 status. This means there is minimal data available for evaluating the efficacy and security of this intervention."
Is there still availability for participants in this experiment?
"Affirmative. Data hosted on clinicaltrials.gov demonstrates that recruitment for this trial is ongoing, with the first post having been made on June 17th 2022 and being last updated on July 27th 2022. This research project seeks to enrol a total of 12 patients at one site."
Share this study with friends
Copy Link
Messenger